Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
DA Monti, E Mitchell, AJ Bazzan, S Littman… - PloS one, 2012 - journals.plos.org
Background Preclinical data support further investigation of ascorbic acid in pancreatic
cancer. There are currently insufficient safety data in human subjects, particularly when …
cancer. There are currently insufficient safety data in human subjects, particularly when …
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis
Background This study aims to comprehensively summarize the currently available
evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced …
evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced …
Molecular characteristics of pancreatic ductal adenocarcinoma
NA Ottenhof, RF de Wilde, A Maitra… - Pathology research …, 2011 - Wiley Online Library
Pancreatic cancer is an almost universally lethal disease and despite extensive research
over the last decades, this has not changed significantly. Nevertheless, much progress has …
over the last decades, this has not changed significantly. Nevertheless, much progress has …
Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa‐miR‐29b‐3p in pancreatic ductal adenocarcinoma
X Zhao, Y Liu, Z Li, S Zheng, Z Wang… - Journal of cellular …, 2018 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Long non‐coding RNAs
(lncRNAs) are important regulators in pathological processes, yet their potential roles in …
(lncRNAs) are important regulators in pathological processes, yet their potential roles in …
The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1
Y Jiang, Z Li, S Zheng, H Chen, X Zhao, W Gao, Z Bi… - Tumor Biology, 2016 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is seriously resistant to radiotherapy and the
mechanism is largely unknown. HOX transcript antisense intergenic RNA (HOTAIR) is …
mechanism is largely unknown. HOX transcript antisense intergenic RNA (HOTAIR) is …
[HTML][HTML] New targeted therapies in pancreatic cancer
Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …
Copper-Catalyzed Consecutive Ullmann, Decarboxylation, Oxidation, and Dehydration Reaction for Synthesis of Pyrrolo or Pyrido[1,2-a]imidazo[1,2-c]quinazolines
W Jiang, Y Li, JQ Liu, XS Wang - Organic Letters, 2023 - ACS Publications
A protocol for a copper-catalyzed intermolecular cross-coupling cascade between 2-(2-
bromoaryl)-1 H-benzo [d] imidazole analogues and proline or pipecolic acid has been …
bromoaryl)-1 H-benzo [d] imidazole analogues and proline or pipecolic acid has been …
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
Y Wang, G Hu, Q Zhang, N Tang, J Guo… - Drug design …, 2016 - Taylor & Francis
Background Pancreatic cancer is considered as a chemoresistant neoplasm with extremely
dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced …
dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced …
[HTML][HTML] 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 …
Y Yue, W Qian, J Li, S Wu, M Zhang, Z Wu, Q Ma… - Cancer Letters, 2020 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, and
chemotherapy is still an important treatment. It is urgent to develop new medicines because …
chemotherapy is still an important treatment. It is urgent to develop new medicines because …
Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis
J Chiramel, AC Backen, R Pihlak, A Lamarca… - International Journal of …, 2017 - mdpi.com
Overexpression of epidermal growth factor receptors (EGFR) occurs in> 90% of pancreatic
ductal adenocarcinomas (PDACs) and is associated with a poorer prognosis. A systematic …
ductal adenocarcinomas (PDACs) and is associated with a poorer prognosis. A systematic …